β-(E)-styrene sulfonyl hydrazide | 13736-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: β-(E)-styrene sulfonyl hydrazide
• 英文别名: -hydrazid；(E)-2-phenylethenesulfonohydrazide
• CAS: 13736-05-5
• 化学式: C₈H₁₀N₂O₂S
• 分子量: 198.246
• InChiKey: IAAHJRFMAIBNGH-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-苄氧基吲哚 、 β-(E)-styrene sulfonyl hydrazide 在 四丁基碘化铵 作用下， 以 1,4-二氧六环 为溶剂， 以74%的产率得到(E)-5-(benzyloxy)-3-(styrylthio)-1H-indole
  参考文献：
  名称：

  TBAI 辅助 β-E-苯乙烯磺酰肼对吲哚的直接 C-H 活化：立体选择性获得 3-苯乙烯基硫代吲哚

  摘要：

  目前的工作描述了通过在各种基材上进行简单的 C-H 活化来引入乙烯基硫醚基团的挑战性。在碘化催化剂叔丁基碘化铵 (TBAI)的辅助下，用 β-( E )-苯乙烯磺酰肼直接 C-H 活化吲哚，得到一系列( E )-苯乙烯基硫代吲哚。因此，β-( E )-苯乙烯磺酰肼与各种取代的吲哚发生自由基交叉偶联反应，以中等至高产率提供结构多样的吲哚乙烯基硫醚。-立体选择性。该方法不含金属催化剂，其价值不仅在于其新颖性，还在于为多种( E )-苯乙烯基硫代吲哚的构型保留提供了一种方便的合成途径。目前的研究为使用 β-( E )-苯乙烯磺酰肼作为化学合成中独特的苯乙烯基硫醇来源铺平了道路。

  DOI：

  10.1039/d1ra02444b

文献信息

• Lewis Base Promoted, Direct 1,4-Conjugate Addition to Quinone Imine Ketals: Efficient Access to Unsymmetrical Diaryl Sulfones
  作者：Teng Liu、Feixiang Cheng、Jianjun Liu、Xianfu Shen、Jianbin Xu、Beifang Nian、Ni He、Shunqun Zeng

  DOI：10.1055/s-0037-1610317

  日期：2019.3

  efficient approach to access an array of diverse unsymmetrical diaryl and heterodiaryl sulfones, aryl alkyl sulfones and aryl vinyl sulfones in good to excellent yields. An alternative approach with eco-friendliness and high efficiency for the preparation of unsymmetrical diaryl sulfones has been developed. The strategy takes advantage of the reaction of sulfonyl hydrazides with quinone imine ketals catalyzed

  ‡新地址：萍乡大学材料与化学工程学院，萍乡337055 15288404381​​@163.com 抽象的 已经开发了具有生态友好性和高效率的另一种制备不对称二芳基砜的方法。该策略利用了DABCO（三亚乙基二胺）在乙醇中催化的磺酰肼与醌亚胺缩酮的反应。该转化通过路易斯碱促进的直接1，4-缀合物加成/磺酰化/醇消除反应序列进行。该协议提供了一种有效的方法，以良好至极好的收率访问各种不对称的二芳基和杂二芳基砜，芳基烷基砜和芳基乙烯基砜。 已经开发了具有生态友好性和高效率的另一种制备不对称二芳基砜的方法。该策略利用了DABCO（三亚乙基二胺）在乙醇中催化的磺酰肼与醌亚胺缩酮的反应。该转化通过路易斯碱促进的直接1，4-缀合物加成/磺酰化/醇消除反应序列进行。该协议提供了一种有效的方法，以良好至极好的收率访问各种不对称的二芳基和杂二芳基砜，芳基烷基砜和芳基乙烯基砜。
• Process for preparation of 3,5-bisalkylphenols
  申请人：——

  公开号：US20040044255A1

  公开（公告）日：2004-03-04

  The invention provides a process for producing a 3,5-bisalkylphenol (2) according to the following reaction scheme: 1 (wherein R 1 represents a hydrogen atom, an alkali metal atom, an alkaline earth metal atom, or a hydroxyl-protecting group (other than methyl group); R 2 represents a C1 to C5 lower alkyl group or an optionally substituted phenyl group; and each of R 3 and R 4 , which may be identical to or different from each other, represents a lower alkyl group, an aralkyl group, or an aryl group); a carbinol compound (1); and a process for producing the carbinol compound. The production process of the present invention enables efficient and safe production of a variety of 3,5-bisalkylphenols including 3,5-diisopropylphenol, which are important as synthesis intermediates for drugs and agricultural chemicals, in shorter steps at high purity in high yield, thus contributing to consistent supply of drugs and agricultural chemicals.

  本发明提供了一种制备3,5-双烷基苯酚(2)的方法，如下反应方程式所示：1（其中R1表示氢原子、碱金属原子、碱土金属原子或羟基保护基（甲基基外）；R2表示C1至C5的低级烷基或可选择取代的苯基；R3和R4各自表示低级烷基、芳基烷基或芳基）。本发明的生产工艺能够高效、安全地生产多种3,5-双烷基苯酚，包括重要的药物和农药合成中间体3,5-二异丙基苯酚，步骤更短、纯度更高、产率更高，从而有助于稳定供应药物和农药。
• Compound Having S1P Receptor Binding Potency and Use Thereof
  申请人：Habashita Hiromu

  公开号：US20080207584A1

  公开（公告）日：2008-08-28

  Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocyclic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof, a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.

  提供的是一个由式(I)表示的化合物：其中，环A和环D分别表示可以具有取代基的环状基团；E和G分别表示具有1至8个原子的主链上的键或间隔物；L表示氢原子或取代基；X表示可以具有取代基的氨基或含有至少一个氮原子且可以具有取代基的杂环基团；n表示0至3，在其中当n为2或更多时，多个环A可以相同或不同。还提供了该化合物的盐、N-氧化物形式、溶剂化物、前药和包括其的药物。该化合物能够结合S1P受体（特别是EDG-1和/或EDG-6），并用于预防和/或治疗移植排斥、自身免疫性疾病、过敏性疾病等。
• Azetidine ring compounds and drugs comprising the same
  申请人：Habashita Hiromu

  公开号：US20070135402A1

  公开（公告）日：2007-06-14

  It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

  本发明旨在提供具有EDG-5拮抗作用的化合物。由于具有EDG-5拮抗作用，式（I）中的化合物：其中每个符号如描述中所定义的，其盐，N-氧化物，溶剂化物或其前药，可用作预防和/或治疗EDG-5介导的疾病的药物，例如血管收缩引起的疾病（例如脑血管痉挛疾病，心血管痉挛疾病，冠状动脉痉挛疾病，高血压，肺动脉高压，肾脏疾病，心肌梗死，心绞痛，心律失常，门脉高压，静脉曲张等），动脉硬化，肺纤维化，肝纤维化，肾脏疾病（例如肾病，糖尿病，高脂血症等）和其他疾病。
• COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF
  申请人：HABASHITA Hiromu

  公开号：US20120064060A1

  公开（公告）日：2012-03-15

  Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocylic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, and when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt, an N-oxide form, a solvate, or a prodrug thereof; and a medicament which includes those. The compound of formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.

  提供了一个由式(I)表示的化合物：（其中，环A和环D分别表示可能具有取代基的环状基团；E和G分别表示具有1-8个原子的主链中的键或间隔物；L表示氢原子或取代基；X表示氨基，可能具有取代基，或者含有至少一个氮原子且可能具有取代基的杂环基团；n表示0-3，当n为2或更多时，多个环A可以相同或不同）。还提供了该化合物的盐、N-氧化物形式、溶剂合物或前药；以及包括这些的药物。式(I)化合物能够结合S1P受体（特别是EDG-1和/或EDG-6），用于预防和/或治疗移植排斥、自身免疫性疾病、过敏性疾病等。